Berobenatide
A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM)
Pfizer · Phase 3 · Recruiting · Enrollment 197
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Treatment Arm 1 | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| Treatment Arm 2 | n/r | n/r | n/r | n/r |
| Treatment Arm 3 | n/r | n/r | n/r | n/r |
| Treatment Arm 4 | n/r | n/r | n/r | n/r |
Not shown
- Treatment Arm 1: endpoint not reported
- Placebo: endpoint not reported
- Treatment Arm 2: endpoint not reported
- Treatment Arm 3: endpoint not reported
- Treatment Arm 4: endpoint not reported